Bexson Biomedical is a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions. Our proprietary formulation technology, SEVALENT, can be applied to small molecules across a broad range of drug classes, enabling traditionally intravenous (IV) therapies to be delivered subcutaneously, and thus, moving treatment out of the clinic/hospital into the home. Our formulation technology is supported by a strong patent portfolio, an experienced management team having over 20 successful FDA approvals, and a world class advisory board led by Robert Langer.
Bexson has validated its formulation technology for a platform of small molecules for therapies that include antivirals, antibiotics, oncology, mental health, and pain management.
Bexson has validated its formulation technology for a platform of small molecules for therapies that include antivirals, antibiotics, oncology, mental health, and pain management.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Pain Management
Lead Product in Development:
BB106
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
